vs
Caribou Biosciences, Inc.（CRBU）与Rocky Mountain Chocolate Factory, Inc.（RMCF）财务数据对比。点击上方公司名可切换其他公司
Rocky Mountain Chocolate Factory, Inc.的季度营收约是Caribou Biosciences, Inc.的1.9倍（$7.5M vs $3.9M），Rocky Mountain Chocolate Factory, Inc.净利率更高（-2.1% vs -672.1%，领先670.1%），Caribou Biosciences, Inc.同比增速更快（89.7% vs -4.4%），Rocky Mountain Chocolate Factory, Inc.自由现金流更多（$-1.3M vs $-21.0M），过去两年Caribou Biosciences, Inc.的营收复合增速更高（27.4% vs 1.9%）
Caribou Biosciences是一家临床阶段生物技术企业，专注研发基于CRISPR基因编辑技术的新一代细胞疗法，适应症覆盖多种癌症与自身免疫疾病，主要在北美、欧洲市场运营，与全球头部药企合作推进治疗管线落地。
落基山巧克力厂是美国知名巧克力企业，同时开展国际特许经营业务，集糖果生产与零售运营于一体，总部位于美国科罗拉多州杜兰戈，除美国本土门店外，在巴拿马、菲律宾也设有经营网点。
CRBU vs RMCF — 直观对比
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $3.9M | $7.5M |
| 净利润 | $-26.5M | $-155.0K |
| 毛利率 | — | 34.0% |
| 营业利润率 | -722.0% | 1.1% |
| 净利率 | -672.1% | -2.1% |
| 营收同比 | 89.7% | -4.4% |
| 净利润同比 | 25.4% | 81.7% |
| 每股收益（稀释后） | $-0.28 | $-0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $3.9M | $7.5M | ||
| Q3 25 | $2.2M | $6.8M | ||
| Q2 25 | $2.7M | $6.4M | ||
| Q1 25 | $2.4M | $8.9M | ||
| Q4 24 | $2.1M | $7.9M | ||
| Q3 24 | $2.0M | $6.4M | ||
| Q2 24 | $3.5M | $6.4M | ||
| Q1 24 | $2.4M | $7.3M |
| Q4 25 | $-26.5M | $-155.0K | ||
| Q3 25 | $-27.5M | $-662.0K | ||
| Q2 25 | $-54.1M | $-324.0K | ||
| Q1 25 | $-40.0M | $-2.9M | ||
| Q4 24 | — | $-847.0K | ||
| Q3 24 | $-34.7M | $-722.0K | ||
| Q2 24 | $-37.7M | $-1.7M | ||
| Q1 24 | $-41.2M | $-1.6M |
| Q4 25 | — | 34.0% | ||
| Q3 25 | — | 23.6% | ||
| Q2 25 | — | 31.1% | ||
| Q1 25 | — | 10.8% | ||
| Q4 24 | — | 23.4% | ||
| Q3 24 | — | 31.8% | ||
| Q2 24 | — | 12.8% | ||
| Q1 24 | — | 24.3% |
| Q4 25 | -722.0% | 1.1% | ||
| Q3 25 | -1337.6% | -7.0% | ||
| Q2 25 | -1784.0% | -2.3% | ||
| Q1 25 | -1823.8% | -30.3% | ||
| Q4 24 | — | -8.9% | ||
| Q3 24 | -1889.2% | -14.3% | ||
| Q2 24 | -1255.8% | -25.4% | ||
| Q1 24 | -1893.9% | -21.7% |
| Q4 25 | -672.1% | -2.1% | ||
| Q3 25 | -1253.3% | -9.7% | ||
| Q2 25 | -2028.4% | -5.1% | ||
| Q1 25 | -1699.6% | -32.5% | ||
| Q4 24 | — | -10.7% | ||
| Q3 24 | -1713.6% | -11.3% | ||
| Q2 24 | -1088.3% | -25.9% | ||
| Q1 24 | -1697.6% | -21.9% |
| Q4 25 | $-0.28 | $-0.02 | ||
| Q3 25 | $-0.30 | $-0.09 | ||
| Q2 25 | $-0.58 | $-0.04 | ||
| Q1 25 | $-0.43 | $-0.38 | ||
| Q4 24 | — | $-0.11 | ||
| Q3 24 | $-0.38 | $-0.11 | ||
| Q2 24 | $-0.42 | $-0.26 | ||
| Q1 24 | $-0.46 | $-0.25 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $12.4M | $641.0K |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $122.2M | $6.0M |
| 总资产 | $175.4M | $20.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $12.4M | $641.0K | ||
| Q3 25 | $11.1M | $2.0M | ||
| Q2 25 | $25.2M | $893.0K | ||
| Q1 25 | $29.4M | $720.0K | ||
| Q4 24 | $16.3M | $1.1M | ||
| Q3 24 | $32.0M | $973.0K | ||
| Q2 24 | $37.9M | $637.0K | ||
| Q1 24 | $49.4M | $2.1M |
| Q4 25 | $122.2M | $6.0M | ||
| Q3 25 | $141.8M | $6.1M | ||
| Q2 25 | $166.1M | $6.7M | ||
| Q1 25 | $217.2M | $7.0M | ||
| Q4 24 | $253.0M | $9.8M | ||
| Q3 24 | $281.2M | $10.5M | ||
| Q2 24 | $310.5M | $9.0M | ||
| Q1 24 | $343.3M | $10.6M |
| Q4 25 | $175.4M | $20.7M | ||
| Q3 25 | $195.0M | $22.3M | ||
| Q2 25 | $220.9M | $20.1M | ||
| Q1 25 | $273.7M | $21.2M | ||
| Q4 24 | $313.3M | $21.6M | ||
| Q3 24 | $344.3M | $21.1M | ||
| Q2 24 | $372.9M | $19.0M | ||
| Q1 24 | $406.8M | $20.6M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-20.8M | $-1.2M |
| 自由现金流经营现金流 - 资本支出 | $-21.0M | $-1.3M |
| 自由现金流率自由现金流/营收 | -533.9% | -16.9% |
| 资本支出强度资本支出/营收 | 5.5% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-112.8M | — |
8季度趋势，按日历期对齐
| Q4 25 | $-20.8M | $-1.2M | ||
| Q3 25 | $-25.2M | $-488.0K | ||
| Q2 25 | $-28.3M | $350.0K | ||
| Q1 25 | $-36.7M | $1.2M | ||
| Q4 24 | $-138.2M | $-2.1M | ||
| Q3 24 | $-32.7M | $-3.5M | ||
| Q2 24 | $-32.9M | $-2.2M | ||
| Q1 24 | $-37.2M | $129.0K |
| Q4 25 | $-21.0M | $-1.3M | ||
| Q3 25 | $-25.3M | $-544.0K | ||
| Q2 25 | $-28.7M | $182.0K | ||
| Q1 25 | $-37.8M | — | ||
| Q4 24 | $-143.1M | — | ||
| Q3 24 | $-33.3M | $-4.6M | ||
| Q2 24 | $-35.1M | $-2.6M | ||
| Q1 24 | $-38.7M | $-352.3K |
| Q4 25 | -533.9% | -16.9% | ||
| Q3 25 | -1151.0% | -8.0% | ||
| Q2 25 | -1075.2% | 2.9% | ||
| Q1 25 | -1605.1% | — | ||
| Q4 24 | -6888.8% | — | ||
| Q3 24 | -1646.9% | -72.6% | ||
| Q2 24 | -1013.5% | -40.2% | ||
| Q1 24 | -1591.2% | -4.9% |
| Q4 25 | 5.5% | 0.5% | ||
| Q3 25 | 5.2% | 0.8% | ||
| Q2 25 | 15.7% | 2.6% | ||
| Q1 25 | 44.3% | — | ||
| Q4 24 | 235.0% | — | ||
| Q3 24 | 33.3% | 17.5% | ||
| Q2 24 | 64.7% | 6.5% | ||
| Q1 24 | 59.6% | 6.6% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRBU
暂无分部数据
RMCF
| Manufacturing | $5.9M | 78% |
| Transferred At Point In Time | $1.2M | 16% |
| Other | $414.0K | 5% |
